The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1543
March 26, 2018
View Complete Issue         Table of Contents 2019 
Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy
March 26, 2018 (Issue: 1543)
The FDA has approved voretigene neparvovec-rzyl intraocular suspension (Luxturna – Spark), an adeno-associated virus vector-based gene therapy, for treatment of confirmed biallelic RPE65 mutation-associated retinal dystrophy in patients who...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy
Article code: 1543c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.